Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease

E Peen, S Almer, G Bodemar, B-O Rydén, C SJölin, K Teje, T Skogh

Department of Internal Medicine, Gastroenterology and Rheumatology Clinics and Department of Medical Microbiology, Transfusion Medicine and Clinical Immunology Laboratory, Faculty of Health Sciences, University Hospital, S-581 85 Linköping, Sweden

E Peen
S Almer
G Bodemar
B-O Rydén
C SJölin
K Teje
T Skogh

Correspondence to: Dr Thomas Skogh, Department of Internal Medicine, Rheumatology Clinic, Faculty of Health Sciences, University Hospital, Linköping, S-581 85, Sweden.

Accepted for publication 12 June 1991

Abstract
Fifty two serum samples from patients with Crohn’s disease, 24 from patients with ulcerative colitis, and 12 from patients with primary sclerosing cholangitis were analysed for the presence of anti-neutrophil cytoplasm antibodies (ANCA) of IgG and IgA class by means of enzyme linked immunosorbent assays using lactoferrin, myeloperoxidase, and α antigen extracted from azurophil granules, ‘α antigen’ (that is, an antigen preparation containing proteinase 3) as substrates. A high frequency of positive tests for IgG anti-lactoferrin antibodies was found in sera from patients with ulcerative colitis (50%) and primary sclerosing cholangitis (50%). In Crohn’s disease only 4 of 52 (8%) sera had anti-lactoferrin antibodies — in all four instances the sera belonged to patients with disease involving the colon. All patients with sclerosing cholangitis and positive tests for anti-lactoferrin had ulcerative colitis. Low levels of IgG antibodies against myeloperoxidase or α antigen were also found occasionally in sera from patients with ulcerative colitis and primary sclerosing cholangitis. IgA antibodies directed against lactoferrin and α antigen (but not myeloperoxidase) were seen in all three conditions.

Since the description of anti-neutrophil cytoplasm antibodies (ANCA) in active Wegener’s granulomatosis, the interest in anti-neutrophil antibodies has increased vastly. ANCA is now recognised as a family of autoantibodies directed against cytoplasmic antigens, mainly lysosomal enzymes, in polymorphonuclear neutrophil leukocytes (PMNL). In Wegener’s granulomatosis, ANCA are typically directed against proteinase 3, a serine proteinase located in azurophilic granules of human PMNL. Antiproteinase 3 antibodies may also occur in isolated, rapidly progressive glomerulonephritis and occasionally in systemic vasculitic conditions other than Wegener’s granulomatosis. Antibodies directed against other lysosomal enzymes in PMNL azurophilic granules, for example myeloperoxidase and elastase, also occur in primary systemic vasculitic diseases and rapidly progressive glomerulonephritis. After ethanol fixation of PMNL, proteinase 3 remains within the cytoplasmic granules, whereas myeloperoxidase and elastase become extracted and locate close to or on the cell nucleus. At indirect immunofluorescent microscopical determination of ANCA, anti-proteinase 3 antibodies produce a typical pancytoplasmatic granular staining pattern (C-ANCA), whereas anti-myeloperoxidase and anti-elastase antibodies give rise to a blurry perinuclear staining pattern (P-ANCA) or staining of the PMNL nuclei (granulocyte specific anti-nuclear antibodies, GS-ANA). A detergent extract of isolated azurophil granules (α antigen) can be used for the detection of anti-proteinase 3 antibodies (C-ANCA) by means of enzyme linked immunosorbent assay (ELISA) but does not allow detection of anti-myeloperoxidase. Also, antibodies against lactoferrin, an iron binding protein residing in specific granules of PMNL, produce a P-ANCA pattern owing to perinuclear/nuclear localisation of lactoferrin after ethanol fixation. Apart from the artificial GS-ANA staining pattern caused by antibodies directed against nucelophilic cytoplasmic antigens, it is possible that true GS-ANAs also exist. Apart from the occurrence in primary systemic vasculitides and rapidly progressive glomerulonephritis, P-ANCA/GS-ANA may be seen in other disease states, for example rheumatoid arthritis without signs of vasculitis, inflammatory bowel disease, and primary sclerosing cholangitis. Recent evidence favours the idea that inflammatory bowel disease may be caused by mesenteric vasculitis.

In a preliminary study of 16 frozen sera from patients with Crohn’s disease we found low levels of anti-α antigen antibodies, anti-myeloperoxidase antibodies, and anti-lactoferrin antibodies in some sera. The present study was done to extend these observations and to include sera from patients with ulcerative colitis and primary sclerosing cholangitis.

Patients and methods
CROHN’S DISEASE
Fifty two patients, 27 men aged 21–71 years (mean 48 years) and 25 women aged 17–55 years (mean 38 years) were enrolled in the study. The mean duration of the disease was 17 years (range 4–33 years). Eight patients had disease limited to the colon and/or rectum, 19 patients had disease in the small bowel alone, and 25 patients had disease manifestations in both small bowel and colon/rectum. Forty patients had been operated on, 14 of whom had been subjected to ileocoecal resection. Three patients had ileorectal anastomosis, and six patients had ileostomy after proctocolectomy.

ULCERATIVE COLITIS
Twenty four patients, 11 men aged 19–65 years
Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease

Figure 1: Diagram to illustrate the ELISA results of IgG autoantibody directed against α antigen, myeloperoxidase, and lactoferrin in sera from patients with Crohn’s disease (n=52), ulcerative colitis (n=24), and primary sclerosing cholangitis (n=12). The lower limit for positive ELISA (that is, +2 SD of the mean value of 218 normal reference sera) is indicated.

Diagnosis had been made by endoscopic retrograde cholangiography 3 years (range 1–6 years) before the study. Two patients had only intrahepatic cholangitis and 10 had both extra- and intrahepatic cholangitis. In four patients cirrhosis of the liver had been diagnosed at histopathological examination of liver biopsies. One patient had undergone liver transplantation 6 years earlier. Nine of the 12 patients had also suffered from ulcerative colitis for 8 years (range 0–21 years) and one had non-specific colitis. In the two remaining patients no accompanying disease had been diagnosed. None of the patients had Crohn’s disease.

One of the patients originally participating in the study had to be excluded as she proved to have suffered from acute Campylobacter jejuni colitis.

ANTIGEN PREPARATIONS
Azurophil granules were prepared from isolated normal peripheral granulocytes after low pressure homogenisation of the cells and centrifugation of the homogenate in a Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden) gradient as described elsewhere. The granules were lysed with 0.01% (final concentration) Triton X-100 (Merck, Darmstadt, Germany). The extract thus achieved (α antigen) was diluted in carbonate-bicarbonate buffer pH 9.5 and used as substrate for ELISA.

Lyophilised preparations of myeloperoxidase (Calbiochem, La Jolla, CA, USA), human milk lactoferrin (Sigma Chemical Co, St Louis, MO, USA), and bovine milk lactoferrin (Sigma) were dissolved in carbonate-bicarbonate buffer (10 μg antigen/ml) and used for ELISA.

ELISA
High binding plastic microtitre plates (Nunc Immunoplate, Roskilde, Denmark) were coated with α antigen, myeloperoxidase, or human lactoferrin solutions by incubation at 4°C for 12 hours. After washing with buffer (phosphate buffered saline, PBS, with 0.05% Tween 20), serum samples (diluted 1:10 in PBS-Tween) were applied for 30 minutes at room temperature. Normal human serum diluted 1:10 served as a blank. The microtitre plates were washed thoroughly with PBS-Tween and incubated for another 30 minutes with alkaline-phosphatase (ALP) conjugated rabbit anti-human γ chain or rabbit anti-human α chain antisera (Dako, Glostrup, Denmark) diluted 1:400 in PBS-Tween. After washing, the substrate buffer was applied and the optical density (OD) read at 405 nm when the positive reference samples had reached OD 1.0. OD values exceeding 2 SDs of the reference material from healthy blood donors (n=218 for IgG tests; n=211 for IgA tests) were considered positive. The IgG autoantibody analyses were performed on all sera from patients with Crohn’s disease (n=52), ulcerative colitis (n=24), and primary sclerosing cholangitis (n=12). IgA autoantibody tests were done on sera from 51 patients with Crohn’s disease, 21 ulcerative colitis sera, and 11 sera from patients with primary sclerosing cholangitis.

PRIMARY SCLerosING CHolangITIS
Twelve patients, seven men aged 20–59 years (mean 46 years), and 13 women aged 20–68 years (mean 42 years) participated in the study. Nineteen patients had left sided colitis and five patients had more extensive or total colitis. Fourteen of the patients had active disease—that is at least five loose stools with visible blood (all had visible inflammation at endoscopy)—and the remaining 10 patients were in clinical remission.

(mean 46 years), and 13 women aged 20–68 years (mean 42 years) participated in the study. Nineteen patients had left sided colitis and five patients had more extensive or total colitis. Fourteen of the patients had active disease—that is at least five loose stools with visible blood (all had visible inflammation at endoscopy)—and the remaining 10 patients were in clinical remission.

(mean 46 years), and 13 women aged 20–68 years (mean 42 years) participated in the study. Nineteen patients had left sided colitis and five patients had more extensive or total colitis. Fourteen of the patients had active disease—that is at least five loose stools with visible blood (all had visible inflammation at endoscopy)—and the remaining 10 patients were in clinical remission.
IgG anti-bovine lactoferrin antibodies were measured essentially as described above, except that no negative or positive serum references were used. OD values were read after 30 minutes incubation with substrate buffer. Eleven positive and 10 negative sera in the test for IgG anti-human lactoferrin were selected for this analysis.

RABBIT ANTI-LACTOFERRIN ANTISERA
Serum containing polyclonal rabbit anti-human leukocyte lactoferrin was the kind gift of Dr Johan Richter, Department of Internal Medicine, University Hospital, Lund, Sweden. To produce anti-human milk lactoferrin antibodies, rabbits were immunised by subcutaneous injections of 2 mg human milk lactoferrin (that is, the same antigen as that used for the ELISA and western blot assays) together with Freund’s incomplete adjuvant (Sigma) on three occasions with 4 week intervals. The reason for not using Freund’s complete adjuvant was to avoid immunisation against hsp-65, because of its immunological cross reaction with human lactoferrin. Two weeks after the second booster dose, the animals were anaesthetised with barbiturate, and exsanguinated by heart puncture. Serum was pooled. Anti-lactoferrin activity of the serum was confirmed by agarose double radial immunodiffusion against human milk lactoferrin.

The rabbit anti-human leukocyte lactoferrin served as a reference. ALP conjugated anti-human IgG and anti-rabbit IgG (Dako) were used as secondary antibodies.

INDIRECT IMMUNOFLUORESCENCE (IIF) MICROSCOPY
To study the distribution of lactoferrin in ethanol fixed granulocytes cyto centrifuged onto microscope slides, the slides were incubated with rabbit anti-human milk lactoferrin in a moist chamber for 30 minutes. After washing with PBS and incubation for another 30 minutes with sheep fluorescein isothiocyanate (FITC) conjugated anti-rabbit Ig (Wellcome Diagnostics, Temple Hill, Dartford, UK), the slides were again washed with PBS, mounted with PBS-glycerin, and inspected under a fluorescence microscope with a mercury lamp (HBO 50) epillumination and filters for FITC activation/emission.

STATISTICS
Differences in ELISA results between the control sera and the patient sera were evaluated by the χ² test, and divided into four groups: p<0.05 = not significant (NS); p<0.05 (*); p<0.01 (**); p<0.001 (***).

Results
The frequencies of IgG antibodies directed against α antigen, myeloperoxidase, and lactoferrin are shown in Figure 1.

In Crohn’s disease 4 of 52 sera had IgG anti-α antigen, which is not statistically different from the control group, although two of the sera had remarkably high antibody levels. In ulcerative colitis 4 of 24 of the sera contained IgG anti-α antigen antibodies (p<0.05), and in primary sclerosing cholangitis 4 of 12 sera (p<0.001) were positive.

IgG anti-myeloperoxidase antibodies occurred in 3 of 52 of the sera taken from patients with Crohn’s disease (not statistically different from

Figure 2: Sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) electrophoresis of the human milk lactoferrin preparation (lane 1) showed only material of molecular weight about 80 kD when stained with Comassie blue. Lane 2 shows molecular weight markers for comparison. Immunoblotting, using polyclonal rabbit anti-human leukocyte lactoferrin, showed slight reaction with antigens of lesser molecular weight, apart from the strong reaction with the 80 kD lactoferrin band (lane 3). Patient sera positive for IgG anti-human milk lactoferrin, as tested by ELISA, however, reacted only with lactoferrin.

Figure 3: Diagram to illustrate the lack of correlation between ELISA results for IgG anti-human lactoferrin autoantibodies and IgG antibodies directed against bovine milk lactoferrin. Ten patient sera positive in the ELISA for IgG anti-human lactoferrin (■) and 12 randomly selected normal reference sera (●) negative in the IgG anti-human lactoferrin test were analysed.
Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease

IgG anti-lactoferrin antibodies were found in 50% of the sera (p<0.001 in both instances). All of the anti-lactoferrin positive cholangitis sera belonged to patients suffering from concomitant ulcerative colitis – that is, 6 of 9 (67%) sera from patients with sclerosing cholangitis and concomitant ulcerative colitis contained IgG anti-lactoferrin antibodies. Two of the sera from patients with primary sclerosing cholangitis and one serum from a patient with ulcerative colitis were positive in all three ELISA tests. However, in all three instances the ELISA tests gave quite different OD values in the different assays, indicating true positive ELISA test results.

Positive anti-lactoferrin ELISA results were blocked by preincubation of the lactoferrin-coated microtiter plates with rabbit IgG anti-lactoferrin (not illustrated). The occurrence of IgG anti-lactoferrin was also confirmed by western blotting, revealing a single reaction band with an antigen of molecular weight about 80,000 and corresponding to rabbit anti-human leukocyte lactoferrin (Fig 2).

One patient originally included in the study had acute colitis and a high level of IgG anti-lactoferrin at the first sampling occasion, and a further raised anti-lactoferrin level in a later serum sample (not illustrated). This patient was, however, excluded from the study since her symptoms were explained by infection with Campylobacter jejuni.

Figure 3 illustrates the lack of correlation between levels of IgG anti-human lactoferrin and IgG anti-bovine lactoferrin as tested by ELISA with 10 sera positive in the anti-human lactoferrin and 12 sera negative in the same test.

Figure 4 shows the occurrence of IgA antibodies directed against α antigen, myeloperoxidase, and human lactoferrin.

Raised levels of IgA anti-α antigen were seen in 12 of 51 (24%) sera from Crohn’s disease (p<0.001), in 5 of 11 (45%) sera from patients with primary sclerosing cholangitis (p<0.001), but in only 2 of 21 (10%) sera from patients with ulcerative colitis (NS). The levels of IgA anti-myeloperoxidase did not differ from the control group in any of the disease states, whereas IgA anti-lactoferrin was significantly (p<0.05) more common in Crohn’s disease, although it was seen only in a minority of the patient sera (5 of 51 = 10%). IgA anti-lactoferrin was found in significantly (p<0.001) increased frequency also in ulcerative colitis (7 of 21 = 33%), but not in sclerosing cholangitis (11 of 59).

The levels of IgA-ANCAs were not explained by the occurrence of agglutinating rheumatoid factors (not illustrated).

Figure 5 shows the frequency of positive IgG and/or IgA tests for either anti-α antigen, or anti-myeloperoxidase, or anti-lactoferrin in sera from blood donors, Crohn’s disease, ulcerative colitis, and primary sclerosing cholangitis. Taken together, positive IgG tests for one or more of the three granulocyte antigens were found in 11% (24 of 218) control sera, in 19% (10 of 52) of Crohn’s disease (NS), in 67% (16 of 24) of ulcerative colitis (p<0.001), and in 67% (8 of 12) of primary sclerosing cholangitis sera; IgA anti-granulocyte antibodies were found in 7% (15 of 211) of the controls, in 29% (15 of 51) of Crohn’s
Discussion

In this study we report high frequencies of IgG anti-lactoferrin antibodies (corresponding to P-ANCA) in sera from patients with ulcerative colitis and primary sclerosing cholangitis. In Crohn’s disease, however, serum anti-lactoferrin antibodies of IgG were rarely detected, and then only in patients with colonic disease manifestations. IgA anti-lactoferrin antibodies were, however, found in some cases of both ulcerative colitis and Crohn’s disease.

Several different types of autoantibodies have been described in inflammatory bowel disease and primary sclerosing cholangitis. Although none of the autoantibodies have been proved to be of pathogenetic significance, it has been shown, both in Crohn’s disease and in ulcerative colitis, that IgG and complement can be present on the apical surface of enterocytes in vivo, possibly indicating a pathogenetic role for anti-epithelial/anti-brush border antibodies in inflammatory bowel disease. In this connection, and considering the high frequency of anti-lactoferrin antibodies found in the present study, it is interesting to note that lactoferrin has been reported to bind to intestinal brush border via a specific receptor. Antibodies of IgG class directed against *Saccharomyces cerevisiae* are common in Crohn’s disease but not in ulcerative colitis, and determination of such antibodies may be of diagnostic help. It is possible that many of the anti-microbial antibodies described in inflammatory bowel disease and other inflammatory disease states, may in fact be reflections of immunisation against microbial heat-shock proteins, which has been implied in the pathogenesis of several autoimmune disease states and which may induce anti-lactoferrin antibodies (see below).

Wakefield et al presented evidence that vasculitis and microthrombosis in mesenteric vessels can be important pathogenetic factors in inflammatory bowel disease. Furthermore, P-ANCA/GS-ANA, which occurs in several primary vasculitis diseases, can frequently be demonstrated in inflammatory bowel disease and primary sclerosing cholangitis also. P-ANCA/GS-ANA is more common in ulcerative colitis than in Crohn’s disease, which is confirmed in the present study by the high frequency of IgG anti-lactoferrin antibodies in ulcerative colitis and primary sclerosing cholangitis but not in Crohn’s disease. In Crohn’s disease the frequency of IgG anti-α antigen and anti-myeloperoxidase antibodies did not differ.
Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease

1. Introduction

Anti-lactoferrin antibodies (ALFAs) were first described in the late 1980s and have since been implicated in various gastrointestinal diseases, including ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease. ALFAs are autoantibodies directed against lactoferrin, a glycoprotein involved in iron uptake and metabolism. The frequency of ALFAs in these diseases has been reported to be significantly higher than in the control group, with a prevalence ranging from 5% to 50% in some studies. However, the clinical significance and pathogenic role of ALFAs in these disorders are still under investigation.

2. Methods

Studies have utilized a variety of techniques to detect ALFAs, including immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence. In some studies, ALFAs have been detected in the sera of patients with ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease. However, the specificity and sensitivity of these assays vary, and further research is needed to standardize the detection methods.

3. Results

In a study by Nielsen et al. (1993), the presence of ALFAs was investigated in patients with ulcerative colitis, primary sclerosing cholangitis, and Crohn’s disease. The results showed that ALFAs were present in 50% of patients with ulcerative colitis, 50% of patients with primary sclerosing cholangitis, and 20% of patients with Crohn’s disease. The authors concluded that these findings suggested a potential role for ALFAs in the pathogenesis of these diseases.

4. Discussion

The presence of ALFAs in these diseases raises questions about their potential role in disease pathogenesis. ALFAs may contribute to the inflammatory response by affecting the iron metabolism of the host, leading to the release of pro-inflammatory cytokines. Furthermore, ALFAs may interact with other autoantibodies, such as ANCA (antineutrophil cytoplasmic antibodies), to form immune complexes that further exacerbate the inflammatory process.

5. Conclusion

Further research is needed to elucidate the role of ALFAs in the pathogenesis of gastrointestinal diseases. The development of more sensitive and specific assays will help in the identification of ALFAs and their potential involvement in disease processes. Additionally, the clinical relevance of ALFAs in these diseases should be investigated to determine their potential as biomarkers or therapeutic targets.

This study was supported by grants from Professor Hanna Swartz Foundation, the Swedish Association against Rheumatism, and the Swedish Medical Research Council.

References


15. Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplas-

24. Skogh T, Heuman R, Tageson C. Anti-brush border anti-
